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Introduction
Bone marrow (BM)-derived myeloid dendritic cells (DC) are highly specialized antigen-presenting cells (APC) that play a critical role in the initiation and modulation of immune responses. 1, 2 Following their migration to lymphoid tissue from the periphery, they serve as potent APC for T cell activation. 1, 3 They also appear to be important in the establishment of central tolerance and in addition, may serve to induce and maintain selftolerance in the periphery. 2, 4 The potent immunostimulatory capacity of mature myeloid DC correlates with high cell surface levels of major histocompatibility complex (MHC) class II antigens and of accessory and costimulatory molecules, that include CD40, CD54, CD58, CD80 (B7-1) and CD86 (B7-2). The interaction of CD28 on T cells with B7 ligands on APC provides an essential second signal for T cell activation. [5] [6] [7] Immature DC, deficient in these molecules (DC progenitors) and that resemble DC freshly isolated from non-lymphoid tissues, can induce antigen-specific T cell anergy in vitro 8 and prolong the survival of cardiac 9 or pancreatic islet allografts. 10 Although these DC exhibit tolerogenic potential, they do not induce permanent graft acceptance. This may be due to the up-regulation of costimulatory molecules on these cells in vivo, following their interaction with host T cells. In principle, prevention or blockade of the expression of B7 ligands could enhance the tolerogenicity of DC, with potential therapeutic implications.
The chimeric fusion protein CTLA4 (cytotoxic T lymphocyte antigen 4) Ig, a homologue of the T cell costimulatory receptor CD28, 11 blocks B7-CD28 interaction, inhibits T cell activation and induces a state of antigenspecific unresponsiveness. 5, 6 It prolongs allograft survival in experimental animals and in some cases, may induce transplantation tolerance. [12] [13] [14] [15] Ex vivo treatment of APC with CTLA4Ig and autoantigen can prevent the development of experimental autoimmune disease in rodents. 16 In this study, we genetically modified BM-derived myeloid DC with an adenoviral (Ad) vector encoding cDNA for CTLA4Ig. Compared with control genetransduced DC, CTLA4Ig-transduced DC expressed substantially reduced cell surface staining for CD86 and were poor inducers of both naive allogeneic T cell proliferation and cytotoxic T lymphocyte (CTL) generation. They were also capable of inducing alloantigen-specific T cell hyporesponsiveness and could be detected, following local injection, in significantly enhanced numbers in the lymphoid tissue of unmodified allogeneic recipients. DC genetically engineered to express immunosuppressive molecules may have potential for the therapy of immunemediated disorders, including allograft rejection and autoimmune disease.
Results
Properties of in vitro generated myeloid DC DC were propagated from B10 mouse BM in response to granulocyte-macrophage colony-stimulating factor (GM-CSF) + interleukin (IL)-4 for 5 days, as described in Materials and methods. These mature DC expressed high cell surface levels of the DC-restricted antigens CD11c and DEC205, and of MHC class II, CD40, CD80, and CD86 (data not shown). As reported previously, 17,18 they were potent stimulators of naive allogeneic (C3H) T cell proliferation, and induced strong CTL responses. Adenoviral (Ad) transduction of DC Replication-deficient Ad vectors encoding the cDNA for CTLA4Ig, or the reporter genes LacZ or EGFP, were constructed under control of the cytomegalovirus (CMV) promoter. BM-derived DC, propagated in GM-CSF + IL-4 for 5 days, were transduced with Ad-LacZ or Ad-EGFP for 2 h at 20°C and at various multiplicities of infection (MOI) in serum-free RPMI-1640. The cells were then maintained for 18 h at 37°C in RPMI-1640 with GM-CSF + IL-4, then transferred for a further 24 h to complete medium. Transduction efficiency with Ad-LacZ was then determined by X-gal staining and was consistently Ͼ80% at MOI of 50-100 (Table 1) . EGFP expression, that allows for both detection and possible sorting of transduced cells by flow cytometry, was determined after the same period and was also consistently Ͼ80% at MOI of 50-100 ( Figure  1 ). Gene expression persisted for at least 7 days in culture as indicated by X-gal staining or flow cytometric analysis (for EGFP + cells). A MOI of 50 was used in all subsequent experiments.
Ad transduction alone does not affect the expression of costimulatory molecules The influence of gene transduction at 50 MOI on the expression of key DC cell surface antigens was determined by immunofluorescence staining using a panel of mAbs and flow cytometry. Expression of the DCrestricted antigen CD11c, MHC class II and costimulatory molecules (CD40, CD80 and CD86) was similar on AdLacZ-transduced DC (50 MOI) when compared with nontransduced cells (data not shown). Thus, surface expression of these molecules was not inherently affected by transduction with Ad vectors at the selected MOI.
Ad-CTLA4Ig-transduced DC exhibit markedly reduced expression of costimulatory molecules DC transduced with cDNA for CTLA4Ig were assessed for the expression of MHC class II and costimulatory molecules, by both flow cytometry and immunocytochemistry. As shown by single and two-color staining, Ad- CTLA4Ig transduced DC exhibited markedly reduced staining for CD86, but not MHC class II on the cell surface when compared with Ad-LacZ-transduced cells ( Figure 2 ). These findings suggested that Ad-CTLA4Ig-transduced DC were secreting the inserted gene product, that then blocked staining for B7 family members.
Supernatants of Ad-CTLA4Ig-transduced DC suppress T cell proliferation To test further for the production of functional gene product, Ad-CTLA4Ig and control Ad-LacZ-transduced DC were harvested 24 h after gene transfer, washed twice, cultured for a further 24 h, then supernatants harvested and assessed for inhibitory activity in primary MLR assays. As shown in Figure 3 , when added at the start of the DC-T cell co-cultures, supernatant from cultures of Ad-CTLA4Ig-transduced DC markedly inhibited naive T cell proliferation induced by GM-CSF + IL-4 propagated allogeneic DC. In contrast, supernatants from Ad-LacZ-DC or Ad-EGFP-DC did not significantly affect T cell proliferation when added at the initiation of the MLR. These observations are consistent with the production of functional CTLA4Ig by the AdCTLA4Ig-transduced DC.
Ad-CTLA4Ig transduction strongly inhibits the capacity of DC to induce allogeneic T cell proliferation We next assessed the stimulatory capacity of Ad-transduced DC in 3-day primary MLR, using purified, naive allogeneic T cells as responders. DC transduced with AdCTLA4Ig at 50 MOI showed marked inhibition of their capacity to induce T cell proliferation ( Figure 4 ). In contrast, DC transduced with a marker gene (Ad-LacZ) retained strong allostimulatory capability, similar to that of non-transduced DC cultured in GM-CSF + IL-4. This indicated that, under these conditions, Ad transduction of DC in and of itself did not impair their allostimulatory capacity.
Ad-CTLA4Ig transduction strongly inhibits the capacity of DC to induce allogeneic CTL generation CTL generation was determined by a standard isotope ( 51 Cr) release assay, using a tumor target cell line syngeneic with the DC stimulators. Assessment of cytotoxicity 6 days after initiation of MLR cultures revealed that the ability of DC expressing CTLA4Ig to induce CTL was markedly inhibited ( Figure 5 ). These findings clearly show that expression of an immunomodulatory transgene by DC can strongly inhibit the induction both of T cell proliferation and the generation of CTL.
Ad-CTLA4Ig-transduced DC induce alloantigen-specific T cell hyporesponsiveness To examine whether the CTLA4Ig gene-transduced DC could induce allogeneic T cell hyporesponsiveness, T cells exposed to Ad-CTLA4Ig-transduced DC in a 2-day primary MLR were first rested for 2 days, then restimulated with donor alloantigens in either secondary MLR or CTL assays, as described in Materials and methods. As shown in Figure 6 , T cells co-cultured originally with allogeneic Ad-CTLA4Ig DC were significantly impaired in their responses to subsequent restimulation by splenocytes from the same strain. This effect was allospecific, as the same T cells responded normally when challenged with third-party splenocytes. In contrast, T cells stimulated in the primary MLR by DC transduced with Ad-a b LacZ retained normal responses to subsequent challenge with alloantigen. Similarly, the cytotoxic activity of C3H T cells primed with Ad-CTLA4Ig B10 DC and subsequently restimulated with normal B10 spleen cells was significantly impaired (Figure 7 ) in an antigen-specific manner. Taken together, these results indicate that DC genetically engineered to express CTLA4Ig can induce alloantigen-specific T cell hyporesponsiveness. Survival of Ad-CTLA4Ig-transduced DC is enhanced in allogeneic recipients A well-described characteristic of DC is their ability to capture antigen and to home to regional lymphoid tissue, where they are believed to present antigen to lymphocytes and modulate immune reactivity. 1, 3 To confirm this property, 5 × 10 5 BM-derived B10 DC propagated in GM-CSF + IL-4 for 5 days were injected s.c. into one hind footpad of normal allogeneic (C3H) mice. Immunohistochemical staining of recipient lymphoid tissue for donor MHC class II (IA b ) revealed IA b+ DC within T cell-dependent areas of the spleen both at 24 h and 7 days after injection. Ad-LacZ-transduced DC (50 MOI) were similarly injected into the footpad of C3H mice and LacZ expression detected by X-gal staining. Ad-LacZ DC were readily demonstrated in the spleen 7 days after injection by donor MHC class II or X-gal staining. Transduction of DC with Ad vectors (50 MOI) did not appear to alter their migratory capacity or survival, as similar numbers of non-transduced and Ad LacZ-transduced DC were detected within recipient spleens (Figure 8 ). Notably however, DC transduced with Ad-CTLA4Ig were detected in significantly increased numbers within the spleen compared with those transduced with Ad-LacZ, or non-transduced DC, 7 days after injection (four-to five-fold increase; P Ͻ 0.001) (Figure 9 ).
Figure 1 (a) Flow cytometric analysis of GM-CSF + IL-4 propagated bone marrow-derived DC transduced with Ad-EGFP, as described in Materials and methods. Typically, Ͼ85% of cells were EGFP

+ . Open profile indicates non-transduced cells. (b) Typical, fluorescent Ad-EGFP transduced cell exhibiting distinct dendritic morphology. (× 400 magnification).
Figure 2 Immunocytochemical staining of cytospin preparations of AdLacZ (control)-and
Discussion
DC capture and process antigens, express lymphocyte costimulatory molecules, secrete proinflammatory cytokines (such as IL-12) and can potently stimulate naive and memory T cell responses. [1] [2] [3] On the other hand, DC also appear to be specialized for the induction of tolerance, both in the thymus and periphery. 2, 4 Maximizing the tolerogenic potential of DC by means that may include their genetic manipulation, offers a potential novel approach to the therapy of immune-mediated disorders, including allograft rejection, autoimmune disease and allergy. Indeed, there is already evidence that immature DC, 8, 19 or DC exposed to ultraviolet (UV) irradiation 20 or immunosuppressive molecules (such as IL-10, transforming growth factor ␤ (TGF␤), or CTLA4Ig) 19, [21] [22] [23] have tolerogenic potential. DC that are inherently deficient in cell surface expression of costimulatory molecules can induce T cell hyporesponsiveness in vitro and prolong allograft survival. 24 In this study, we have shown that myeloid DC propagated in vitro with GM-CSF + IL-4 can be transduced using a replication-deficient Ad vector to express the gene encoding CTLA4Ig. This chimeric fusion protein is a potent immunosuppressant that blocks the expression of B7 costimulatory molecules on APC [5] [6] [7] and that suppresses both experimental allograft rejection [12] [13] [14] [15] and autoimmune disease. 16 The data also reveal that CTLA4Ig-transduced DC have markedly impaired ability to induce T cell proliferation and CTL generation. Furthermore, the results demonstrate the potential of CTLA4Ig-transduced DC to induce (alloantigen-specific) T cell hyporesponsiveness and to survive in increased numbers in the lymphoid tissue of normal, MHC mismatched allogeneic recipients.
Gene therapy to achieve therapeutic immunosuppression for application in transplantation and autoimmune disease is at an early stage of development. [25] [26] [27] The range of gene transfer technologies available includes the use of viral vectors, naked and plasmid DNA, bioballistic particulate delivery and liposomes with nucleic acid. Viral vectors have the advantage (over nonviral systems) of enabling highly efficient gene transfer and comparatively long-term transgene expression, since they use mechanisms of infection employed by wild-type viruses to proliferate intracellularly. Long-term expression of replication-deficient recombinant Ad vectors can be achieved in mice given immunosuppressive agents. 28 Various approaches to gene therapy of allograft rejection have been examined. These include donor MHC gene transfer to recipient thymus 29 or BM. 30, 31 Thus, retroviral constructs have been employed for ex vivo transfer of MHC class I genes into recipient hematopoietic cells to confer specific hyporesponsiveness to allogeneic skin grafts. Alternatively, transfection of donor organs with 51 
Figure 7 Priming of T cells with CTLA4Ig-transduced DC reduces subsequent CTL responses to alloantigen. Allogeneic T cells (C3H) primed with Ad-CTLA4Ig-transduced DC (B10) or Ad LacZ (control)-transduced DC in primary MLR were purified, rested for 48 h, then restimulated with bulk B10 splenocytes for 96 h before testing against
Cr-labeled donor-specific (EL4) target cells. Results are means ±1 s.d. of triplicate wells and are representative of two separate experiments.
cDNA encoding immunosuppressive proteins (eg vIL-10, TGF␤, Fas ligand (L) (CD95L), or CTLA4-Ig) [32] [33] [34] [35] has been used to prolong graft survival significantly. Genetic modification of autoreactive T cells to express IL-10, 36, 37 or local delivery of IL-4 by retrovirus-transduced T cells 38 can ameliorate experimental autoimmune disease in mice. Transfer of a variety of genes, including IL-1 receptor (R) antagonist, 39 Fas L, 40 soluble (s)IL-1R or tumor necrosis factor (TNF) ␣R 41 to the site of inflammation ameliorates experimental antigen-induced arthritis.
Since DC constitutively express MHC antigens, home to T-dependent areas of lymphoid tissue, and interact selectively with host T cells, they are attractive targets for genetic manipulation to improve the outcome of allograft survival. Candidate genes include cytokines and other molecules that undermine the allostimulatory role of DC and include viral (v) IL-10, 42,43 TGF␤, 19, 44 Fas L, 23, 45 CTLA4Ig, 16, 23 CD40Ig and nitric oxide. 18 By using viral vectors to modify DC in vitro, there is in principle reduced administration of viral proteins, in contrast to direct in vivo administration of viral vectors, thus minimizing the generation of antiviral Abs that can prevent repetition of treatment. Of the transfection methods available, gene delivery to DC by replication-defective Ad vectors is by far the most efficient. Thus, DC have been designed to express IL-12 or tumor antigens for the therapy of cancer, [46] [47] [48] or viral antigens for the treatment of infections, such as HIV. To date, however, there have been no published reports of the properties of DC genetically engineered to express an immunosuppressive molecule.
Transgenic expression of CTLA4Ig by DC, resulting in augmentation of their tolerogenic potential, offers a novel strategy that could be applied in several clinical situations where inhibition of undesired immune reactivity is required. Whereas in small animals, CTLA4Ig has been shown to promote tolerance to allo-or autoantigen, the resulting systemic immunosuppression could lead to undesirable side-effects. On the other hand, limiting expression of the molecule to DC and the site of DC-T cell interaction, would allow for selective immunosuppression of T cells reacting with the antigen borne by the DC. In transplantation, infusion of costimulatory molecule-deficient DC of donor origin has been shown to prolong cardiac and pancreatic islet allograft survival, although not indefinitely.
9,10 Late in vivo up-regulation of costimulatory molecules on these allogeneic DC would in principle, be suppressed or counteracted by the continued expression of transgenic CTLA4Ig, further enhancing their potential for tolerance induction. Indeed, treatment of sensitized recipients with donor Ag and CTLA4 Ig during the effector phase of the immune response (after cardiac engraftment) has resulted in longterm graft survival in 50% of rat recipients. 49 Blockade of costimulation at such a relatively late phase of the immune response could be augmented by the prolonged expression of CTLA4Ig by donor DC.
The markedly reduced costimulatory molecule expression observed on the CTLA4Ig-transduced DC, their low allostimulatory activity, potential to induce T cell hyporesponsiveness, apparent normal migratory activity and increased survival potential in vivo may be useful predictors of the potential therapeutic efficacy of genetically modified DC in vivo. The presentation by donor DC of alloantigens, together with the absence of second signal, plus local production of an immunosuppressive molecule, such as CTLA4Ig, is likely to promote the inhibition of antidonor reactivity and potentiate tolerance induction. Our current approach to enhancing the tolerogenicity of DC also includes culture with cytokines, such as IL-10 or TGF␤, that promote a 'tolerogenic' phenotype. 19, 22 and transduction of DC with multiple immunosuppressant genes, that may exert complementary inhibitory effects on immune reactivity.
In summary, we present evidence that primary cultures of murine myeloid DC can be adenovirally transduced to express stably an immunosuppressive molecule. CTLA4Ig-transduced DC generated by this method exhibit selective reduction in the expression of costimulatory molecules and markedly impaired capacity to induce CTL responses. Moreover, CTLA4Ig-transduced DC show potential for the induction of alloantigen-specific T cell hyporesponsiveness and enhanced survival in allogeneic hosts. The findings suggest that genetic engineering of DC to express CTLA4Ig or other immunosuppressive molecule(s) may be a promising therapeutic modality in transplantation and possibly other immunemediated disorders, including autoimmune disease. Propagation and purification of BM-derived DC BM cells harvested from femurs of normal B10 mice were cultured in 24-well plates (2 × 10 6 per well) in 2 ml of RPMI-1640 (Life Technologies, Gaithersburg, MD, USA) supplemented with antibiotics and 10% v/v fetal calf serum (FCS) (referred to subsequently as complete medium), 4 ng/ml recombinant (r) mouse (m) granulocyte-macrophage colony-stimulating factor (GM-CSF) and 1000 U/ml rm IL-4 (Schering Plough, Kenilworth, NJ, USA). The procedure used to generate DC was similar to that described initially by Inaba et al, 50 with minor modifications. 17, 51 The medium containing GM-CSF + IL-4 was refreshed every 2 days; after gentle swirling of the plates, half of the old medium was aspirated and an equivalent volume of fresh, cytokine-supplemented medium added. This method was implemented to deplete nonadherent granulocytes without dislodging clusters of developing DC that attached loosely to a monolayer of firmly plastic-adherent macrophages. Nonadherent, low buoyant density cells released spontaneously from the clusters were harvested after 5-7 days. DC were purified by centrifugation over metrizamide (to approximately 90% purity), as described. 18 Flow cytometry Cell surface Ag expression was analyzed by cytofluorography, using an EPICS ELITE flow cytometer (Coulter Corporation, Hialeah, FL, USA). Staining with primary hamster or rat monoclonal antibodies (mAbs), including rat antimouse CD40, CD80 or CD86 (PharMingen, San Diego, CA, USA) was followed by fluorescein isothiocyanate (FITC)-conjugated goat antihamster or goat antirat IgG2a, as described. 51 MHC class II staining was performed using biotin-conjugated mouse antimouse mAbs with FITC streptavidin as the secondary reagent. 51 Construction of recombinant adenoviral (Ad) vectors Ad vectors (⌬E1, ⌬E3) were constructed through Cre-lox recombination using the pAd-lox shuttle vector and 5 helper virus DNA in the adenoviral packaging cell line CRE-8. 52 To construct Ad-EGFP, a SnaBI-HpaI fragment containing part of the CMV promoter, the EGFP N1 cDNA and part of the SV40 poly A derived from pEGFP N1 (Clontech, Palo Alto, CA, USA) was inserted into the shuttle vector pAdlox. To construct Ad-CTLA4Ig, a HindIII-EcoRI fragment containing the mCTLA4mIgG3 cDNA was inserted in the shuttle vector. The recombinant adenoviruses were generated by cotransfection of SfiI-digested pAdlox-EGFP N1 or pAdlox-mCTLA4mIgG3 and 5 helper virus DNA into the CRE8 cell line, propagated and purified as described. 52 Ad vector-mediated gene transfer and expression in DC in vitro All Ad vectors were propagated in CRE-8 cells, purified by two rounds of CsCl density centrifugation, dialyzed and stored at −70°C in 3% sucrose. The titer of viral stock was determined by plaque-forming assay using 293 cells. All vector preparations were demonstrated to be free of replication-competent adenovirus. To assess the ability of Ad vectors to transfer and express genes in BM-derived DC, the cells cultured for 5 days were infected with AdLacZ or AdEGFP for 2 h at various MOI. Two days later, lacZ or EGFP expression was quantified by X-gal staining or by flow cytometry, respectively.
Materials and methods
Mixed leukocyte reactions (MLR)
These were performed using nylon wool-purified splenic T cells as responders, as described previously in detail. 51 Cr release was determined after the plates had been incubated for 4 h at 37°C in 10% CO 2 in air. An aliquot (100 l) of supernatant was recovered from each well after centrifugation at 500 g for 1 min. Maximum 
Testing for T cell hyporesponsiveness
For primary MLR, 2 × 10 6 T cells were incubated with 5 × 10 5 unmodified DC or Ad-Laz-or Ad-CTLA4Ig-transduced DC stimulators in 24-well plates in 2 ml medium per well. After 48 h, the cells were harvested, washed in medium and depleted of Ia + cells with anti-IA b mAb (Pharmingen) plus low-toxicity rabbit complement (Accurate Chemical and Scientific, Westbury, NY, USA). 51 Viable cells were isolated by centrifugation over Ficoll-Isopaque for 15 min at 350 g then rested in medium for 48 h in the absence of stimulators. The primed T cells were restimulated with freshly isolated, ␥-irradiated spleen cells in a secondary, 72 h MLR in 96-well, round-bottomed plates. For the final 18 h, 10 l 3 HTdR (1 Ci) was added to each well. Cultures were harvested on to glass fiber disks using a multiple cell harvester and the degree of thymidine incorporation was determined in a liquid scintillation counter. Results were expressed as mean c.p.m. ± 1 s.d. Alternatively, secondary MLR were set up in 24-well plates for 96 h. The restimulated T cells were then harvested and used as effectors in CML assays, as described above.
In vivo DC migration Gene-transduced or unmodified control B10 (H2 b ) DC were injected s.c. (5 × 10 5 cells in 50 l) into one hind footpad of normal allogeneic recipients (C3H; H2 k ). At various times thereafter, groups of three mice were killed and the draining popliteal lymph node and spleen were removed, embedded in Tissue-Tek (OCT Compound, Miles, Elkart, IN, USA) and frozen at −70°C. Cryostat sections (5 m) were air-dried at room temperature overnight, then stored at −70°C until further processing.
Immunohistochemistry
Donor MHC class II
+ (IA b+ ) cells were identified in cryostat sections using biotinylated mouse IgG2a anti-mouse IA b (Pharmingen) in an avidin-biotin-alkaline phospha-tase complex (ABC) staining procedure, as described. 53 Controls included sections of normal donor or recipient strain tissues. The incidence of donor MHC class II + (Ia b+ ) cells in sections was determined by the mean number of positive cells per 100 high power fields (hpf).
Statistical analysis
The significance of differences between means was determined using Student's t test; a P value of Ͻ0.05 was considered significant.
